MedTrace Logo

Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone

NCT01089790 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2011-09-21

No results posted yet for this study

Summary

This study will evaluate the long-term safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM).

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Dutogliptin

400 mg tablet, once daily

DRUG

Sitagliptin

100 mg capsule (each capsule contains two 50-mg tablets), once daily

Sponsors & Collaborators

  • Phenomix

    collaborator INDUSTRY

  • Forest Laboratories

    lead INDUSTRY

Principal Investigators

  • Kaity Posada, PharmD · Forest Research Institute, a subsidiary of Forest Laboratories Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
86 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01089790 on ClinicalTrials.gov